Form 4: Tarsus Pharmaceuticals Director Rosemary A. Crane Acquires Stock Options and Restricted Stock Units

Director Rosemary A. Crane acquired stock options and restricted stock units in Tarsus Pharmaceuticals, Inc. related to her service as a non-employee director.

Summary

• Rosemary A. Crane, a director at Tarsus Pharmaceuticals, Inc., filed a Form 4 indicating changes in beneficial ownership.
• On June 13, 2024, Crane acquired 5,000 stock options with an exercise price of $33.14, vesting fully on June 12, 2034, contingent on continuous service.
• Additionally, Crane acquired 3,350 Restricted Stock Units (RSUs), each representing a right to receive one share of common stock, vesting fully on the one-year anniversary of the grant date, also contingent on continuous service.
• Following these transactions, Crane directly owns 5,000 stock options and 3,350 RSUs.
• The transactions are related to Crane's service as a non-employee director as of the company's 2024 annual meeting of stockholders.
• Scott Sieckert, Attorney-in-Fact, signed the document on June 14, 2024, under a power of attorney.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options and RSUs to a director is a routine event, but it also indicates confidence in the company's future.

Positives

• The acquisition of stock options and RSUs by a director signals confidence in the company's future performance.
• The vesting conditions tied to continuous service align the director's interests with those of the shareholders.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options and RSUs.

Industry Context

This filing is a routine disclosure of insider transactions, common in the pharmaceutical industry, where stock-based compensation is frequently used to incentivize directors and executives.

Comparison to Industry Standards

• Stock option and RSU grants are a standard component of compensation packages for non-employee directors in publicly traded companies, particularly in the pharmaceutical and biotechnology sectors.
• Companies like Amgen, Gilead Sciences, and Biogen routinely grant similar equity-based awards to their directors.
• The vesting schedules, typically one year, are also in line with industry norms to ensure continued service and alignment with shareholder interests.

Stakeholder Impact

• The granting of stock options and RSUs aligns the director's interests with those of the shareholders, potentially leading to better corporate governance and decision-making.
• Employees may view this as a positive sign, indicating the company's commitment to incentivizing its leadership.

Key Dates